The initial phase II study will test single and repeated doses of BIIB014 in patients with late-stage Parkinson’s disease, in addition to the usual L-dopa therapy. The second phase II study will be a trial of BIIB014 monotherapy in patients with early-stage Parkinson’s disease. The primary endpoint of both studies will be to evaluate the safety and tolerability of BIIB014. Secondary endpoints will include the evaluation of motor function.
Simon Sturge, CEO of UK biotech firm Vernalis, said: “The progress into phase II trials is of particular significance to Vernalis’ growing Parkinson’s disease franchise and further demonstrates the company’s ongoing commitment to the Parkinson’s community.”
Vernalis received a milestone payment of $3 million at the end of 2006 relating to the start of the phase II program from Biogen.